As the mass of third-quarter data grows, it's only become clearer how COVID-19 testing is shaping fortunes for diagnostics makers in 2020. Building on big gains reported by Abbott, Thermo Fisher and Quest, LabCorp and Quidel last week posted respective revenue growth of 33% and 276%. Meanwhile, the trend of a return to year-over-year revenue growth at device companies turned mixed, as elective procedure-dependent Smith & Nephew and Boston Scientific reported declines, albeit significantly improved from the second quarter.
This week will feature more data points on diagnostics from COVID-19 testing heavyweights Hologic and BD and on the interoperable insulin pump market from Insulet and Tandem. Also releasing results are Cardinal Health, Invitae, Guardant Health, Zimmer Biomet and Hillrom.
